Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia


Cite item

Full Text

Abstract

Objective. To evaluate occurrence, variety, structural peculiarities and prognostic meaning of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia (ALL) receiving therapy according to ALL-2009 protocol. Materials and methods. The study included 115 adult patients with firstly diagnosed Ph-negative ALL: 58 male and 57 female aged from 15 to 61 years (mean age 26.5 years), who underwent treatment from September 2009 to September 2015 in National Medical Research Center for Hematology MH RF (n=101) and in hematology departments of regional hospitals (n=14). All patients received therapy of ALL-2009 protocol (ClinicalTrials.gov, NCT01193933). The median follow-up was 24.5 months (0.2-94.4 months). As a part of the study results of a standard cytogenetic assay (SCA) were analyzed and fluorescence hybridization in situ (FISH) with the use of DNA-probes was performed on archived biological material for structural changes in gene locuses MLL/t(11q23), с-MYC/t(8q24), TP53/ deletion 17p13, CDKN2A/ deletion 9p21, translocation t(1;19)/E2A-PBX1 и t(12;21)/ETV6-RUNX1; iAMP21 identification. Results. Karyotype was defined using SCA in 86% of patients. Normal karyotype was found in 48.5% of them, chromosome aberrations in 51.5% (structural changes were found in 19.2%, hyperploidy in 27.2%, and hypoploidy in 5.1%). In 17.2% of patients complex karyotype abnormalities were found. With the use of FISH technique aberrations were found in 67% of patients: 9p21/CDKN2A deletion in 24.3%, MLL/t(11q23) gene abnormalities in 7.8%, 17p13/TP53 deletion in 5.2%, abnormalities of c-MYC/t(8q24) in 1.7%, t(1;19)/E2A-PBX1 in 0.8%, and iAMP21 in 0.8%, other abnormalities (additional signals/absence of signals from gene locuses) in 26.4%, t(12;21)/ETV6-RUNX1 was not found. FISH technique use in addition to SCA allows to increase aberrant karyotype location from 51.5 to 67%. A statistically significant correlation of 9p21/CDKN2A deletion with high serum lactate dehydrogenase activity (p=0.02); MLL/t(11q23) gene abnormalities - with leucocytosis and high blast cells level in blood (p=0.0016), hyperploidy - with normal leukocyte count (p=0.02) was shown. In groups with different cytogenetic abnormalities no statistically significant differences of treatment with ALL-2009 protocol were found (in terms of complete remission, early mortality and treatment resistance). When connection of cytogenetic abnormalities and their combinations with long-term results were analyzed according to ALL-2009 protocol, only two characteristics - MLL/t(11q23) and c MYC/t(8q24) gene abnormalities had a statistically significant influence on disease-free survival (HR - 176.9; p<0.0001) and chance of recurrence (HR - 6.4; p=0.02) Conclusion. Adverse prognostic factors in terms of therapeutic management provided in ALL-2009 protocol were MLL/t(11q23) and с-MYC/t(8q24) genes abnormalities. CDKN2A/9p21 and TP53/17p13 genes deletions, quantative and complex karyotype abnormalities were not prognostic factors in adult patients with Ph-negative ALL in ALL-2009 protocol use.

About the authors

I S PISKUNOVA

National Research Center for Hematology

Email: piskunova.i@blood.ru
врач-гематолог отд-ния интенсивной химиотерапии гематологических заболеваний со стационаром дневного пребывания; http://orcid.org/0000-0003 -1571-3161 Moscow, Russia

T N OBUKHOVA

National Research Center for Hematology

к.м.н., зав. лаб. кариологии; http://orcid.org/0000-0002 -3273-6640 Moscow, Russia

E N PAROVICHNIKOVA

National Research Center for Hematology

д.м.н., руководитель отдела интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения со стационаром дневного и круглосуточного пребывания больных и трансплантации костного мозга; http://orcid.org/0000-0001- 6177-3566 Moscow, Russia

S M KULIKOV

National Research Center for Hematology

к.т.н., зав. информационно-аналитическим отделом Moscow, Russia

V V TROITSKAYA

National Research Center for Hematology

к.м.н., зав. отд-нием интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения со стационаром дневного и круглосуточного пребывания больных; http://orcid.org/0000-0002- 4827-8947 Moscow, Russia

O A GAVRILINA

National Research Center for Hematology

к.м.н., н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения со стационаром дневного и круглосуточного пребывания больных; http://orcid.org/0000-0002- 9969-8482 Moscow, Russia

V G SAVCHENKO

National Research Center for Hematology

акад. РАН, проф., генеральный директор; http://orcid.org/0000-0001- 8188-5557 Moscow, Russia

References

  1. Волкова С.А., Боровков Н.Н. Основы клинической гематологии: Учебное пособие. Н. Новгород: Издательство Нижегородской гос. медицинской академии, 2013: 72-73. ISBN 978-5-7032-0882-3.
  2. Паровичникова Е.Н., Троицкая В.В., Соколов А.Н., Клясова Г.А., Кузьмина Л.А., Ахмерзаева З.Х., Гаврилина О.А., Басхаева Г.А., Лукьянова И.А. , Кравченко С.К. , Грибанова Е.О. , Бондаренко С.Н., Баранова О.Ю., Капорская Т.С., Рыльцова Т.В., Зотина Т.П., Зинина Е.Е., Самойлова О.С., Елуферьева А.С., Гаврилова Л.В., Константинова Т.С., Лапин В.А., Приступа А.С., Капланов К.Д., Обухова Т.Н. , Гальцева И.В., Русинов М.А., Куликов С.М., Савченко В.Г. Острые Ph - негативные лимфобластные лейкозы взрослых: факторы риска на протоколе ОЛЛ-2009. Терапевтический архив. 2016; 88(7): 15-24. PMID: 27459610
  3. Паровичникова Е.Н., Троицкая В.В., Соколов А. Н., Ахмерзаева З.Х., Кузьмина Л. А., Менделеева Л. П., Клясова Г. А., Кравченко С. К., Грибанова Е. О., Бондаренко С. Н., Баранова О. Ю., Капорская Т. С., Рыльцова Т.В., Низамутдинова А.С., Загоскина Т.П., Зинина Е.Е., Самойлова О.С., Климович А.В., Карякина Е.А., Елуферьева А.С., Гаврилова Л.В., Константинова Т.С., Торопова И.Ю., Приступа А.С., Вопилина Н.А., Тикунова Т.С., Скаморина О.П., Капланов К.Д., Обухова Т.Н., Гальцева И.В., Русинов М.А., Куликов С.М., Савченко В.Г. Промежуточные результаты по лечению острых Ph - негативных лимфобластных лейкозов у взрослых больных (итоги Российской исследовательской группы по лечению острых лимфобластных лейкозов (RALL)). Онкогематология. 2014; 9(3): 6-15. doi: 10.17650/1818-8346-2014-9-3-6-15
  4. An International System for Human Cytogenetic Nomenclature. Edit. F.Mitelman. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Publ. in collaboration with Cytogenetics and Cell Genetics. ISCN, 1995.
  5. Shih L.Y, Chou T.B, Liang D.C, Tzeng Y.S, Rubnitz J.E, Downing J.R, Pui C.H. Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan. Leukemia. 1996; 10(9): 1456-1458. PMID: 8751462
  6. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, Tafuri A, Vignetti M, Vitale A, Cuneo A, Castoldi G, Saglio G, Pane F, Mecucci C, Camera A, Specchia G, Tedeschi A, Di Raimondo F, Fioritoni G, Fabbiano F, Marmont F, Ferrara F, Cascavilla N, Todeschini G, Nobile F, Kropp M.G, Leoni P, Tabilio A, Luppi M, Annino L, Mandelli F, Foà R. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005; 105(9): 3434-3441. doi: 10.1182/blood-2004-07-2922
  7. Moorman A.V, Harrison C.J, Buck G.A, Richards S.M, Secker-Walker L.M, Martineau M, Vance G.H, Cherry A.M, Higgins R.R, Fielding A.K, Foroni L, Paietta E, Tallman M.S, Litzow M.R, Wiernik P.H, Rowe J.M, Goldstone A.H, Dewald G.W. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007; 109 (8): 3189-3197. doi: 10.1182/blood-2006-10-051912
  8. The Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique. Blood. 1996; 87(8): 3135-3142. PMID: 8605327
  9. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela J.M, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J. GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK). Allogeneic transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006; 20: 2155-2161. doi: 10.1038/sj.leu.2404420
  10. Wetzler M, Dodge R.K, Mrózek K, Carroll A.J, Tantravahi R, Block A.W, Pettenati M.J, Le Beau M.M, Frankel S.R, Stewart C.C, Szatrowski T.P, Schiffer C.A, Larson R.A, Bloomfield C.D. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999; 93(11): 3983-3993. PMID: 10339508
  11. Na Xu, Yuling Li, Xuan Zhou, Rui Cao, Huan Li, Qi-si Lu, Lin Li, Zi-yuan Lu, Ji-xian Huang, Jing Sun, Qi-fa Liu, Qing-feng Du, Xiao-li Liu. CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult BLineage Acute Lymphoblastic Leukemia Patients. Cancer. 2015; 6(11): 1114-1120. doi: 10.7150/jca.11959
  12. Anu Usvasalo, Suvi Savola, Riikka Raty, Kim Vettenranta, Arja Harila-Saari, Pirjo Koistinen, Eeva-Riitta Savolainen, Erkki Elonen, Ulla M. Saarinen-Pihkala, Sakari Knuutila. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults - CGH study. Leukemia Research. 2008; 32: 1228-1235. doi: 10.1016/j. leukres.2008.01.014
  13. Kim M, Yim S, Cho N, Kang S.H, Ko D.H, Oh B, Kim T.Y, Min H.J, She C.J, Kang H.J, Shin H.Y, Ahn H.S, Yoon S.S, Kim B.K, Shin H.R, Han K.S, Cho H.I, Lee D.S. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood Blineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study. Cancer Genet Cytogenetic. 2009; 195: 59-65. doi: 10.3892/ol.2016.4169
  14. Slany R. The molecular biology of mixed lineage leukemia. Haematologica. 2009; 94 (7): 984-993. doi: 10.3324/haematol.2008.002436
  15. Christine J. Harrison, Anthony V. Moorman, Kerry E. Barber, Zoë J. Broadfield, Kan L. Cheung, Rachel L. Harris, G. Reza Jalali, Hazel M. Robinson. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukemia: a UK Cancer Cytogenetics Group study. Br J Haematol. 2005; 129(4): 520-530. doi: 10.1111/j.1365-2141.2005. 05497.x
  16. Johansson B, Moorman A.V, Haas O.A, Watmore A.E, Cheung K.L, Swanton S, Secker-Walker L.M. on behalf of the European 11q23 Workshop participants. Hematologic malignancies with t(4;11)(q21;q23) - a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants. Leukemia. 1998; 12(5): 779-787. doi: 10.1038/sj.leu.2401012
  17. Pui C.H, Gaynon P.S, Boyett J.M, Chessells J.M, Baruchel A, Kamps W, Silverman L.B, Biondi A, Harms D.O, Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002; 359(9321): 1909-1915. doi: 10.1016/S0140-6736(02)08782-2
  18. Raimondi S.C, Peiper S.C, Kitchingman G.R, Behm F.G, Williams D.L, Hancock M.L, Mirro J. Childhood acute lymphoblastic leukemia with chromosomal breakpoints at 11q23. Blood. 1989; 73(6): 1627-1634.
  19. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017; 31: 705-711. doi: 10.1038/leu.2016.263
  20. Angi M, Kamath V, Yuvarani S, Meena J, Sitaram U, Manipadam M.T, Nair S, Ganapule A, Fouzia N.A, Abraham A, Viswabandya A, Poonkuzhali B, George B, Mathews V, Srivastava A, Srivastava V.M. The t(8;14)(q24.1;q32) and its variant translocations: A study of 34 cases. Hematol Oncol Stem Cell Ther. 2017; 10(3): 126-134. doi: 10.1016/j.hemonc.2017.03.002
  21. Harewood L, Robinson H, Harris R, Al Obaidi M.J, Jalali G.R, Martineau M, Moorman A.V, Sumption N, Richards S, Mitchell C, Harrison C.J. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia. 2003 (Mar); 17(3): 547-53. doi: 10.1038/sj.leu.2402849
  22. Jabbar Al-Obaidi M.S, Martineau M, Bennett C.F, Franklin I.M, Goldstone A.H, Harewood L, Jalali G.R, Prentice H.G, Richards S.M, Roberts K, Harrison C.J. ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia. Leukemia. 2002; 16(4): 669-674. doi: 10.1038/sj.leu.2402435

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies